BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32048382)

  • 21. Diagnostic Value of the EZH2 Immunomarker in Malignant Effusion Cytology.
    Ang PP; Tan GC; Karim N; Wong YP
    Acta Cytol; 2020; 64(3):248-255. PubMed ID: 31352449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The value of exfoliative cell cytology in the diagnosis of exudative pleural effusions.
    Tetikkurt C; Yılmaz N; Tetikkurt S; Gundogdu Ş; Disci R
    Monaldi Arch Chest Dis; 2018 Sep; 88(3):944. PubMed ID: 30203633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.
    Savic S; Franco N; Grilli B; Barascud Ade V; Herzog M; Bode B; Loosli H; Spieler P; Schönegg R; Zlobec I; Clark DP; Herman JG; Bubendorf L
    Chest; 2010 Jul; 138(1):137-44. PubMed ID: 20139227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of flower pot cells in effusion cytology.
    Bharani V; Singh P; Gupta N; Srinivasan R
    Diagn Cytopathol; 2017 Oct; 45(10):925-927. PubMed ID: 28560851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
    Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
    Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reassessing the optimal volume for malignancy detection in serous fluid cytology.
    Coconubo DM; Baskota SU; Li R; Srivastava P; Cuda J; Khader S
    Cancer Cytopathol; 2022 Jul; 130(7):551-557. PubMed ID: 35468659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial.
    Maskell NA; Gleeson FV; Davies RJ
    Lancet; 2003 Apr; 361(9366):1326-30. PubMed ID: 12711467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis.
    Stevens MW; Leong AS; Fazzalari NL; Dowling KD; Henderson DW
    Diagn Cytopathol; 1992; 8(4):333-41. PubMed ID: 1638933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.
    Hatem L; McIntire PJ; He B; Gogineni S; Ho M; Mathew S; Margolskee EM; Siddiqui MT; Rao RA
    Diagn Cytopathol; 2019 Mar; 47(3):160-165. PubMed ID: 30520251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The diagnostic yield of pleural fluid cytology in malignant pleural effusions.
    Ong KC; Indumathi V; Poh WT; Ong YY
    Singapore Med J; 2000 Jan; 41(1):19-23. PubMed ID: 10783675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Young investigator challenge: MicroRNA-21/MicroRNA-126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology.
    Cappellesso R; Nicolè L; Caroccia B; Guzzardo V; Ventura L; Fassan M; Fassina A
    Cancer Cytopathol; 2016 Jan; 124(1):28-37. PubMed ID: 26765063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic Accuracy of a Limited Immuno-panel of Calretinin and Ber-EP4 for Diagnosis of Malignant Effusions.
    Khurram N; Anis T; Yusuf NW
    J Coll Physicians Surg Pak; 2019 Jan; 29(1):33-36. PubMed ID: 30630566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions.
    Davidson B; Stavnes HT; Hellesylt E; Hager T; Zeppa P; Pinamonti M; Wohlschlaeger J
    Hum Pathol; 2016 Jan; 47(1):104-8. PubMed ID: 26520416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology.
    Granados R; Cibas ES; Fletcher JA
    Acta Cytol; 1994; 38(5):711-7. PubMed ID: 8091903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurement of telomere length in cells from pleural effusion: Asbestos exposure causes telomere shortening in pleural mesothelial cells.
    Aida S; Aida J; Naoi M; Kato M; Tsuura Y; Natsume I; Takubo K
    Pathol Int; 2018 Sep; 68(9):503-508. PubMed ID: 30098092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mesothelial cell. Cytology. Cytochemistry. Immunocytochemistry. Contribution of immunolabelling to the cytodiagnosis of serous effusions with cells of mesothelial aspect].
    Marsan C; Gaulier A; Sabatier P; Garcia R
    Arch Anat Cytol Pathol; 1993; 41(5-6):223-8. PubMed ID: 8135583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Laboratory Discrimination Between Neutrophilic Malignant and Parapneumonic Pleural Effusions.
    Lee J; Lee YH; Seo H; Lee H; Kim YK; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH
    Am J Med Sci; 2019 Aug; 358(2):115-120. PubMed ID: 31331448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.
    Augeri S; Capano S; Morone S; Fissolo G; Giacomino A; Peola S; Drace Z; Rapa I; Novello S; Volante M; Righi L; Ferrero E; Ortolan E; Funaro A
    Oncotarget; 2018 Apr; 9(32):22785-22801. PubMed ID: 29854315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.